It has also been found to be efficacious and safe in the clinical setting (NCT03836105) of metastatic cutaneous squamous cell carcinoma [162]. A phase II clinical trial (NCT04243616) is ongoing to check therapeutic responses upon neoadjuvant chemotherapy and cemiplimab treatment in patients with high-risk or progressive HR + and HER2 − breast cancer or TNBC. Here, ERBB2 is linked to breast cancer.